Table 3.
Clinical trials and outcomes after CD45RA-depleted donor lymphocyte infusions after haploidentical HCT.
| Authors | Diagnosis/ Patient Number |
Transplantation Platform | Cell Dose | Survival | CI of aGvHD | CI of cGvHD |
|---|---|---|---|---|---|---|
| Dunkaina, M. et al. BMT 2021 [49] | Children with hematologic malignancies (n = 143) |
TCR αβ depletion MAC conditioning Haplo (n = 69) MUD (n = 6) MSD (n = 1) |
Prophylactic—day 0: 25 × 103 cell/kg, day 30, 60, 90, 120 50 × 103 cell/kg Median number of DLI given = 4 (range: 1–5) |
2y OS: 79% 2y DFS: 72% | Grade II–IV: 14.5% Grade III–IV: 8% |
2y: 6% |
| Naik, S. et al. Blood 2021 [47] | Children with acute leukemia (n = 30) |
TCR αβ depletion | Prophylactic two weeks following engraftment: DL1: 1 × 105 cells/kg DL2: 1 × 106 cells/kg DL3: 1 × 107 cells/kg |
1y OS: 86.3% 1y DFS:69.8% |
Grade II–IV: 26.7% Grade III–IV: 13.3% |
None |
| Castagna, L. et al. Transpl. Cell Ther. 2021 [50] | Adults with hematologic malignancies (n = 19) |
Post-transplant cyclophosphamide; MAC/RIC |
Prophylactic DLI of 3 infusions each 4–6 weeks apart First dose given at median of 55 days (range, 46–63) post HCT DL1 5 × 105 cells/kg DL2 1 × 106 cells/kg DL3 5 × 106 cells/kg |
1y OS: 79% 1y DFS: 75% |
Grade I–IV 6% | 1y: 15% |
MAC: myeloablative conditioning; RIC: reduced-intensity conditioning; MSD: matched sibling donor; MUD: matched unrelated donor.